A Study of BON-C1393 in Adults With Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BON-C1393 in Patients With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-C1393 monotherapy or in combination with other anticancer regimens in adults with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Dose Exploration) and Phase 1b (Dose Expansion).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Advanced solid tumors are malignant cancers that develop in organs of the body. They spread to other parts of the body and may reoccur after treatment, or no longer respond to available therapies or surgery. Many people with advanced solid tumors have limited treatment options, and their cancer may continue to grow or spread. Therefore, there is an ongoing need to develop novel therapies that may improve tumor control and prolong survival.
BON-C1393 is a targeted cancer medicine called an antibody-drug conjugate (ADC). An ADC consists of an antibody linked to a drug that can kill cancer cells. The antibody part of BON-C1393 attaches to proteins that are found on the surface of cancer cells. After it attaches to these proteins, BON-C1393 enters the cancer cell where the drug causes DNA damage and cell death.
The purpose of this study is to test whether BON-C1393 is safe and if it can help treat adults with selected advanced solid tumors.
This study consists of 2 parts, one called dose escalation and dose exploration (Phase 1a) and one called dose expansion (Phase 1b). During the dose escalation and dose exploration part, the study doctors will test different doses of the study drug to find the recommended dose that people can take without having serious side effects.
During the dose expansion part, the study doctors will test the study drug in a larger number of people using the doses identified from Phase 1a. The study will enroll adults with advanced solid tumors at multiple centers in the Asia-Pacific region.
The overall time to participate in this study is approximately 9 months for Phase 1a and approximately 12 months for Phase 1b. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Director
- Numero di telefono: 1.877.828.5568
- Email: clinicaltrials@beonemed.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic solid tumor intolerant, refractory to or progressing after standard systemic therapies.
-
Must be able to provide archival tumor tissue (formalin-fixed, paraffin-embedded tissue block (FFPE) block or approximately 10-15 freshly cut unstained FFPE slides)
-
Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.0
-
Must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study drug(s):
a. Must not have required blood transfusion or growth factor support ≤ 14 days before sample collection at screening for the following:
-
Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
-
Platelets ≥ 100 × 109/L.
-
Hemoglobin ≥ 90 g/L. b. Estimated glomerular filtration rate (GFR) ≥ 50 mL/min, as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) c. Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (total bilirubin must be ≤ 3 × ULN with direct bilirubin ≤ 1.5 × ULN for patients with Gilbert's syndrome).
d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN or < 5 × ULN if hepatic metastases are present.
e. Albumin ≥ 2.0 g/dL. f. In Phase 1b Part D, for patients receiving combination therapy with bevacizumab, additional inclusion criteria are listed below:
-
Urine dipstick for proteinuria < 2+ (within 7 days prior to initiation of study treatment). Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.
-
Coagulation parameters: international normalized ratio (INR) of ≤ 1.5 (or an in-range INR of ≤ 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) < 1.2 × ULN.
-
Female of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 7 months after the last dose of BON-C1393, for ≥ 6 months after the last dose of bevacizumab or capecitabine, whichever comes later. They must also have a negative urine or serum pregnancy test result ≤ 3 days before first dose of study drug/treatment.
-
Nonsterile male must be willing to use condom and refrain from sperm donation for the duration of the study and for ≥ 4 months after the last dose of BON-C1393, for ≥ 3 months after the last dose of capecitabine, whichever comes later.
Exclusion Criteria:
- Prior treatment with any B7 homolog 3 (B7-H3) or integrin beta-6 (ITGB-6) -targeted antibody-drug conjugate (ADCs) or ADCs containing topoisomerase inhibitor (TOP) inhibitor as payload.
- History of severe allergic reactions, severe reaction to infusion, or hypersensitivity to the active ingredient and excipients of the study drug(s) or protein-based therapeutics.
- Unable to comply with the requirements of the protocol, unless the written approval of the medical monitor has been obtained before informed consent.
- Active hepatitis C.
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
- Any major surgical procedure ≤ 28 days (or ≤ 14 days for low-invasive cases [eg, colostomy]) before the first dose of study drug. Must have recovered adequately from the surgery and/or complications from the surgical procedures before the first dose of study drug/treatment.
Any of following treatments before the first dose of study drug:
-
Prior systemic anticancer therapy (including targeted therapy and immunomodulators [eg, interleukin (IL), interferon, thymosin, etc]) ≤ 14 days, ≤ 28 days for immuno-oncological antibody, ≤14 days or 5 half-lives (whichever is shorter) for chemotherapy, ADCs, or investigational therapy.
-
Radiation therapy (curative) and palliative radiation therapy to the chest ≤ 4 weeks; ≤ 2 weeks for palliative radiation therapy to other areas (ie, limited field and 10 or fewer days or fractions) including whole-brain radiotherapy.
-
Chinese patent medicine with anticancer activity approved by the China National Medical Products Administration (NMPA) (regardless of the type of cancer) ≤ 14 days.
-
Herbal remedies with immune-stimulating properties (eg, mistletoe extract) or that are known to potentially interfere with liver or other major organ functions (eg, hypericin) ≤ 14 days or 5 half-lives, whichever is shorter or known.
- Ongoing treatment with a strong cytochrome cytochrome (CYP)3A inhibitor, or strong CYP3A inducer, or strong CYP1A2 inhibitor, or strong CYP1A2 inducer.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1a Part A: Monotherapy Dose Escalation
Sequential cohorts of increasing dose levels of BON-C1393 will be evaluated. |
Administered intravenously |
|
Sperimentale: Phase 1a Part B: Monotherapy Dose Exploration
Participants with select advanced solid tumors will receive BON-C1393 at 2 - 3 selected dose levels that have been determined to be safe in Part A. |
Administered intravenously |
|
Sperimentale: Phase 1b Part C: Monotherapy Dose Expansion
Participants with select advanced solid tumors will receive BON-C1393 as monotherapy at the recommended doses for expansion (RDFEs) identified in Phase 1a. |
Administered intravenously |
|
Sperimentale: Phase 1b Part D: Dose Expansion Combination Therapy
Participants with select advanced solid tumors will receive BON-C1393 in combination with bevacizumab and capecitabine. |
Administered orally Administered intravenously Administered intravenously |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)
Lasso di tempo: Approximately 1 month
|
Approximately 1 month
|
|
|
Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Lasso di tempo: Up to approximately 9 months
|
Up to approximately 9 months
|
|
|
Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator
Lasso di tempo: Up to approximately 12 months
|
ORR is defined as the percentage of participants with a best overall response (BOR) of partial response (PR) or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to approximately 12 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator
Lasso di tempo: Up to approximately 9 months
|
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to approximately 9 months
|
|
Phase 1a: Duration of Response (DOR) Assessed by the Investigator
Lasso di tempo: Up to approximately 9 months
|
DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 9 months
|
|
Phase 1b: Duration of Response (DOR) Assessed by the Investigator
Lasso di tempo: Up to approximately 12 months
|
DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 12 months
|
|
Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator
Lasso di tempo: Up to approximately 9 months
|
DCR is defined as the percentage of participants with a BOR of a CR, PR, or stable disease (SD) per RECIST v1.1. |
Up to approximately 9 months
|
|
Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator
Lasso di tempo: 12 Weeks
|
DCR at 12 weeks is defined as the percentage of participants with CR, PR, or SD per RECIST v1.1, and are alive and progression-free at Week 12. |
12 Weeks
|
|
Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator
Lasso di tempo: 24 weeks
|
DCR at 24 weeks is defined as the percentage of participants with CR, PR, or SD according to RECIST v1.1, and are alive and progression-free at the Week 24. |
24 weeks
|
|
Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator
Lasso di tempo: Up to approximately 12 months
|
PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 12 months
|
|
Area Under the Concentration Time Curve (AUC) of BON-C1393
Lasso di tempo: Up to approximately 3 months
|
Up to approximately 3 months
|
|
|
Maximum Observed Plasma Concentration (Cmax) of BON-C1393
Lasso di tempo: Up to approximately 8 months
|
Up to approximately 8 months
|
|
|
Time to Maximum Plasma Concentration (Tmax) of BON-C1393
Lasso di tempo: Up to approximately 8 months
|
Up to approximately 8 months
|
|
|
Terminal Half-Life (t1/2) of BON-C1393
Lasso di tempo: Up to approximately 3 months
|
Up to approximately 3 months
|
|
|
Plasma Concentrations of BON-C1393
Lasso di tempo: Up to approximately 12 months
|
Up to approximately 12 months
|
|
|
Phase 1b: Number of Participants with Adverse Events
Lasso di tempo: Up to approximately 12 months
|
Up to approximately 12 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Study Director, BeOne Medicines
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Aminoacidi, peptidi e proteine
- Proteine
- Composti eterociclici, 1-anello
- Composti eterociclici
- Acidi nucleici, nucleotidi e nucleosidi
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Nucleosidi
- Uracile
- Pirimidinoni
- Deossiribonucleosidi
- Fluorouracile
- Capecitabina
- Bevacizumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BON-C1393-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Periodo di condivisione IPD
See plan description
Criteri di accesso alla condivisione IPD
See plan description
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .